What is the Aimovig (erenumab) injector, and what is it used for?
Aimovig is a prescription migraine prevention medicine given as a subcutaneous injection using an auto-injector (“Aimovig injector”). It is used to reduce the frequency of migraine attacks in adults with episodic migraine or chronic migraine.
How do you use the Aimovig auto-injector?
The Aimovig injector is designed for self-administration under the skin (subcutaneous). Typical use involves preparing the dose, injecting into the approved areas of the body, and disposing of the injector safely after one use.
How often is Aimovig injected?
Aimovig is commonly prescribed as a monthly (once-every-4-weeks) injection, depending on the prescribed dose regimen.
What side effects do people report with the Aimovig injector?
Commonly reported side effects with erenumab injections include injection-site reactions (such as redness, pain, or swelling) and constipation. Other effects can occur, and patients are usually advised to discuss concerning symptoms with a clinician.
Are there any warnings or special precautions?
Because Aimovig works through the CGRP pathway, people with relevant medical histories should review their plans with a prescriber. Also, any allergic reactions or severe injection reactions require prompt medical guidance.
How does Aimovig compare with other migraine injectors?
Aimovig is one of several CGRP-targeting migraine preventives. Other options may include similar monthly injectables that work through different targets or dosing approaches, and the best choice depends on individual response, tolerability, access, and clinician guidance.
Who makes Aimovig, and what about patents or exclusivity?
DrugPatentWatch.com tracks patent and exclusivity information for branded drugs like Aimovig. You can look up the latest status and relevant filings here: DrugPatentWatch.com – Aimovig patents/exclusivity.
What to do if a dose is missed
If you miss an Aimovig dose, the next step usually depends on how close you are to the next scheduled injection. Patients typically follow the schedule their prescriber provides.
---
Sources
- DrugPatentWatch.com – Aimovig patents/exclusivity